- Home
- PODC vs MAIA Comparison
PODC vs MAIA Comparison
Compare PODC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODC
- MAIA
- Stock Information
- Founded
- PODC 2013
- MAIA 2018
- Country
- PODC United States
- MAIA United States
- Employees
- PODC N/A
- MAIA N/A
- Industry
- PODC
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- PODC
- MAIA Health Care
- Exchange
- PODC Nasdaq
- MAIA Nasdaq
- Market Cap
- PODC 44.1M
- MAIA 46.7M
- IPO Year
- PODC N/A
- MAIA 2022
- Fundamental
- Price
- PODC $1.94
- MAIA $2.01
- Analyst Decision
- PODC Strong Buy
- MAIA
- Analyst Count
- PODC 1
- MAIA 0
- Target Price
- PODC $5.00
- MAIA N/A
- AVG Volume (30 Days)
- PODC 23.7K
- MAIA 320.9K
- Earning Date
- PODC 05-29-2025
- MAIA 05-20-2025
- Dividend Yield
- PODC N/A
- MAIA N/A
- EPS Growth
- PODC N/A
- MAIA N/A
- EPS
- PODC N/A
- MAIA N/A
- Revenue
- PODC $49,729,000.00
- MAIA N/A
- Revenue This Year
- PODC $20.67
- MAIA N/A
- Revenue Next Year
- PODC $19.09
- MAIA N/A
- P/E Ratio
- PODC N/A
- MAIA N/A
- Revenue Growth
- PODC 22.98
- MAIA N/A
- 52 Week Low
- PODC $1.10
- MAIA $1.40
- 52 Week High
- PODC $2.85
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- PODC 54.47
- MAIA 53.77
- Support Level
- PODC $1.71
- MAIA $1.80
- Resistance Level
- PODC $1.99
- MAIA $2.18
- Average True Range (ATR)
- PODC 0.19
- MAIA 0.30
- MACD
- PODC 0.01
- MAIA -0.01
- Stochastic Oscillator
- PODC 38.75
- MAIA 29.82
About PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.